For anyone not hip-deep in the hot field of artificial intelligence (AI), its role in drug discovery — or in any endeavor, for that matter — can feel vague, especially relative to the concrete problems drugmakers face daily. The very definition of AI can seem fuzzy, touted at times as capable of doing everything from organizing your photos to driving your car. Yet, in the biopharma space, as dollars flow in and candidates rise up, clarity is surfacing, too, program by program, bringing with it a more down-to-earth explanation of how the technology is reshaping the discovery enterprise. Read More
The heightened attention that biopharma companies are paying to hot new technologies in the immuno-oncology and gene and cell therapy areas is translating to a significant increase in research and development investments being made by the sector. Drug discovery, however, does not come cheap, as evidenced from an in-depth analysis conducted by BioWorld Insight. Read More
